Vaccines Europe conducted a pipeline review of its 15 member companies, including information up to August 2023.
The review shows a promising vaccines pipeline aimed at tackling the challenges of today and tomorrow, such as the burden of respiratory tract infections, AMR, the ageing of the population, climate change and zoonotic infections, through leveraging a broad array of technology platforms.
Download pipeline review
Chikungunya Virus |
Clostridioides difficile infection (CDI) |
Coronaviruses |
Cytomegalovirus |
Dengue fever |
Epstein-Barr virus (EBV) infection |
Glioblastoma (CMV-positive) |
Gonorrhoea |
Group B Streptococcus Infection |
Hepatitis B |
Herpes simplex virus |
Human immunodeficiency virus (HIV) |
Human metapneumovirus and RSV (hMPV/RSV) |
Human papillomavirus (HPV) |
Influenza |
Invasive Escherichia Coli Disease |
Klebsiella pneumoniae |
Lyme disease (Borreliosis) |
Malaria |
Meningococcal disease |
Nipah virus (NiV) |
Norovirus |
Pneumococcal disease |
Rabies |
Respiratory Syncytial Virus (RSV) |
Salmonella |
Shigellosis |
Varicella-Zoster Virus |
Yellow fever |
Zika |